🚀 RECENT AI SUCCESS

Our AI successfully predicted the gap for $AYI and executed a BUY strategy, securing a +1.14% net profit.

UPGRADE TO SEE LIVE SIGNALS

$HYL.BR

Hyloris Pharmaceuticals SA

European UnionEUROPEAN UNION
FREE PREVIEW
🌐 Website🏛️ Euronext Brussels📁 Health Technology🏭 Pharmaceuticals Major
AVG HISTORICAL GAP-2.18%
MAX GAP RECORD-2.18%
PREMIUM
AI ACCURACY RATE
92.4%
Unlock AI Insights 🔓

LAST 10 EARNINGS GAPS (%)

VOLATILITY & BIAS PROFILE

AVG VOLATILITY2.2%
Bullish Gaps
Bearish Gaps
Neutral

Intelligence Brief

Hyloris Pharmaceuticals SA engages in the provision of development and reformulating of pharmaceutical products. It offers commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a novel, dual modeof-action non-opioid analgesic for the treatment of post-operative pain. The company was founded by Stijn van Rompay and Thomas Jacobsen in 2012 and is headquartered in Liege, Belgium. Read full dossier

CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL